273 related articles for article (PubMed ID: 29275178)
1. Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia.
Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Patel H; Pandey D; Patel D; Bahekar R; Jain M
Biomed Pharmacother; 2018 Feb; 98():364-371. PubMed ID: 29275178
[TBL] [Abstract][Full Text] [Related]
2. Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition.
Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Pandey D; Patel H; Ranvir R; Kadam S; Patel D; Bahekar R; Jain M
Chem Biol Interact; 2018 Feb; 282():13-21. PubMed ID: 29325849
[TBL] [Abstract][Full Text] [Related]
3. Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model.
Patel V; Joharapurkar A; Kshirsagar S; Patel HM; Pandey D; Patel D; Sutariya B; Patel M; Bahekar R; Jain MR
Drug Res (Stuttg); 2017 Dec; 67(12):730-736. PubMed ID: 28898910
[TBL] [Abstract][Full Text] [Related]
4. Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid Hormone.
Patel VJ; Joharapurkar AA; Kshirsagar SG; Sutariya BK; Patel MS; Bahekar RH; Jain MR
Curr Mol Pharmacol; 2019; 12(2):139-146. PubMed ID: 30747091
[TBL] [Abstract][Full Text] [Related]
5. Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease.
Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Patel H; Pandey D; Patel D; Ranvir R; Kadam S; Bahekar R; Jain M
Cardiovasc Hematol Agents Med Chem; 2018; 16(1):35-43. PubMed ID: 29357809
[TBL] [Abstract][Full Text] [Related]
6. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease.
Patel V; Joharapurkar A; Kshirsagar S; Patel M; Sutariya B; Patel H; Pandey D; Patel D; Ranvir R; Kadam S; Bahekar R; Jain M
Can J Physiol Pharmacol; 2018 Jun; 96(6):587-596. PubMed ID: 29406832
[TBL] [Abstract][Full Text] [Related]
7. Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice.
Burmeister MA; Ferre T; Ayala JE; King EM; Holt RM; Ayala JE
Am J Physiol Endocrinol Metab; 2012 Feb; 302(3):E334-43. PubMed ID: 22094469
[TBL] [Abstract][Full Text] [Related]
8. Central GLP-1 receptor activation improves cholesterol metabolism partially independent of its effect on food intake.
Patel V; Joharapurkar AA; Kshirsagar SG; Patel KN; Bahekar R; Shah G; Jain MR
Can J Physiol Pharmacol; 2016 Feb; 94(2):161-167. PubMed ID: 26629909
[TBL] [Abstract][Full Text] [Related]
9. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
[TBL] [Abstract][Full Text] [Related]
10. Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors.
Vishnoi S; Bhattacharya S; Walsh EM; Okoh GI; Thompson D
J Chem Inf Model; 2023 Aug; 63(15):4934-4947. PubMed ID: 37523325
[TBL] [Abstract][Full Text] [Related]
11. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice.
Hsieh J; Longuet C; Baker CL; Qin B; Federico LM; Drucker DJ; Adeli K
Diabetologia; 2010 Mar; 53(3):552-61. PubMed ID: 19957161
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
[TBL] [Abstract][Full Text] [Related]
13. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice.
Gu W; Lloyd DJ; Chinookswong N; Komorowski R; Sivits G; Graham M; Winters KA; Yan H; Boros LG; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2011 Jul; 338(1):70-81. PubMed ID: 21471191
[TBL] [Abstract][Full Text] [Related]
15. GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr
Patel A; Yusta B; Matthews D; Charron MJ; Seeley RJ; Drucker DJ
Mol Metab; 2018 Oct; 16():45-54. PubMed ID: 29937214
[TBL] [Abstract][Full Text] [Related]
16. Combination of Lorcaserin and GLP-1/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-obese Mice.
Patel V; Joharapurkar A; Kshirsagar S; Patel M; Savsani H; Bahekar R; Jain M
Drug Res (Stuttg); 2020 Aug; 70(8):376-384. PubMed ID: 32645724
[TBL] [Abstract][Full Text] [Related]
17. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.
Zimmermann T; Thomas L; Baader-Pagler T; Haebel P; Simon E; Reindl W; Bajrami B; Rist W; Uphues I; Drucker DJ; Klein H; Santhanam R; Hamprecht D; Neubauer H; Augustin R
Mol Metab; 2022 Dec; 66():101633. PubMed ID: 36356832
[TBL] [Abstract][Full Text] [Related]
18. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.
Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Patel K; Bahekar R; Shah G; Jain M
Can J Physiol Pharmacol; 2013 Dec; 91(12):1009-15. PubMed ID: 24289070
[TBL] [Abstract][Full Text] [Related]
19. Central and Peripheral Glucagon Reduces Hyperlipidemia in Rats and Hamsters.
Patel V; Joharapurkar A; Kshirsagar S; Patel HM; Pandey D; Patel D; Shah K; Bahekar R; Shah GB; Jain MR
Drug Res (Stuttg); 2017 Jun; 67(6):318-326. PubMed ID: 28445900
[TBL] [Abstract][Full Text] [Related]
20. Effect of GLP-1 based therapies on diabetic dyslipidemia.
Patel VJ; Joharapurkar AA; Shah GB; Jain MR
Curr Diabetes Rev; 2014; 10(4):238-50. PubMed ID: 24998439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
